Scienmag

JANUARY 28, 2021

Credit: itabajara da Silva Vaz Jr) A tick saliva study reveals immune responses that could lead to better protection for cattle.

Immune Response 52

Immune Response Protein Scientist Allergies 52

pharmaphorum

SEPTEMBER 1, 2020

The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response. The trial is assessing efficacy and safety of the vaccine in all participants, and local and systemic reactions and immune responses will be assessed in 3,000 participants.

Vaccination 69

Vaccination Vaccine Trials Immune Response 69

XTalks

JANUARY 20, 2021

Researchers at KU Leuven in Belgium have found a potential mechanism underlying irritable bowel syndrome (IBS) that involves activation of immune cells primed by past gastrointestinal infections. However, IBS patients do not have allergies to any given foods, nor any gastrointestinal conditions, such as celiac disease.

Immune Response 52

Immune Response Research Allergies Protein 52

The Pharma Data

SEPTEMBER 1, 2020

The US part of the study will be funded by the National Institutes of Health and Biomedical Advanced Development Authority and the National Institute of Allergy and Infectious Diseases. AstraZeneca says it wants to enroll over 50,000 volunteers across the world. Conor Kavanagh. Source link.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Scienmag

JULY 6, 2021

Researchers at Karolinska Institutet in Sweden publish new findings in the journal Cancer Discovery showing how pharmacological activation of the protein p53 boosts the immune response against tumours. Given its ability to react […].

Immune Response 40

Immune Response Protein Development Research 40

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. The phase 1 study that is being run by the National Institute of Allergy and Infectious Diseases tests three dose levels of the vaccine, mRNA-1273, given in two injections a month apart in 120 adults.

Vaccination 53

Vaccination Vaccine Research Trials 53

XTalks

SEPTEMBER 21, 2023

The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. This groundbreaking endeavor has received support from the National Institute of Allergy and Infectious Diseases (NIAID). mRNA, 2) BG505 MD39.3 gp151 CD4KO mRNA.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

The Pharma Data

DECEMBER 23, 2020

Cellular (T cell) response were observed to multiple regions of the spike protein including the RBD region. 74% had measurable cellular responses at the 1.0 mg dose group demonstrated cellular responses. The 1.0 mg and 2.0 mg dose group and 84% demonstrating neutralizing antibodies in the 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

The Pharma Data

NOVEMBER 17, 2020

It currently has several vaccines in its pipeline, among which are the HIV-1/AIDS, intra-nasal Influenza and malaria, and collaborative projects in the field of allergy immunotherapy and in oncology. For further information, please visit www.mymetics.com. Forward looking statements.

Vaccination 40

Vaccination Vaccine Containment Development 40

Scienmag

NOVEMBER 12, 2020

Inhaled delivery of a formulation of a key protein involved in the immune response – interferon beta-1a – to hospitalised COVID-19 patients in the UK reduced the odds that they would develop severe disease or die from SARS CoV-2 infection.

Immune Response 75

Immune Response Protein Clinical Trials Clinical Trials 75

Pharmaceutical Technology

FEBRUARY 3, 2023

The Janssen vaccines studied in the Imbokodo and Mosaico studies were based on the mosaic concept, where they were intentionally designed to include a broader immunogen that could be used everywhere, says Dr. Mary Marovich, director of the Vaccine Research Program at National Institute of Allergy and Infectious Diseases (NIAID).

Vaccination 293

Vaccination Vaccine Antibody Trials 293

XTalks

MAY 17, 2024

Led by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID), World AIDS Vaccine Day emphasizes the importance of awareness and education in the fight against HIV/AIDS. It’s a day to celebrate the scientific strides made towards a vaccine and to remember the work that still lies ahead.

Vaccination 52

Vaccination Vaccine Research Immune Response 52

pharmaphorum

FEBRUARY 28, 2021

“Importantly, the vaccine was 100 percent effective in protecting against death from the disease everywhere it was tested,” commented Anthony Fauci, director of the National Institute for Allergy & Infectious Disease (NIAID). “To The vaccine causes the body to create its own copies of the protein, stimulating an immune response.

Vaccination 59

Vaccination Vaccine Immune Response Protein 59

XTalks

NOVEMBER 30, 2023

Its mechanism of action involves blocking the protein shell (capsid) of the HIV-1 virus, disrupting multiple crucial stages of the viral lifecycle. Developed by Gilead, Sunlenca is the first drug in a novel class known as capsid inhibitors to receive FDA approval for treating HIV-1. In November 2023, Hookipa Pharma Inc.,

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Pfizer

NOVEMBER 2, 2022

The vaccine candidate is based on BioNTech’s proprietary mRNA platform technology and contains mRNA strands encoding the wild-type spike protein of SARS-CoV-2 and the spike protein of the Omicron BA.4/BA.5 Hemagglutinin is a surface protein of the influenza virus which plays a role in the initiation of infection. INDICATION.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

The Pharma Data

MARCH 13, 2022

That’s because the mutations that led to the variant’s emergence aren’t found in the regions of the virus that stimulates one type of cellular immune response, says an international research team from Johns Hopkins Medicine, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and ImmunoScape, a U.S.-Singapore

Immune Response 52

Immune Response Protein Medicine Genetics 52

Delveinsight

JANUARY 21, 2021

Drugs that target the cancer-promoting proteins MDM2 and BET have been attempted in acute myeloid leukaemia (AML) and have not been all that effective on their own. The combination appears to work by activation of the tumour-suppressing protein p53, they announced. The gene TP53 produces the protein p53, a known tumour suppressor.

Research 52

Research Protein Clinical Trials Clinical Trials 52

Scienmag

MAY 13, 2021

The new […].

Immune Response 53

Immune Response Antibody Protein Vaccination 53

Scienmag

JUNE 25, 2021

Changes to the ‘spike’ protein explain Alpha’s faster spread, and how the Beta variant evades immune responses, suggesting the need for a booster with an updated vaccine Credit: Bing Chen, PhD, Boston Children’s Hospital New SARS-CoV-2 variants are spreading rapidly, and there are fears that current COVID-19 vaccines won’t (..)

Immune Response 75

Immune Response Vaccination Vaccine Protein 75

The Pharma Data

JANUARY 29, 2021

1.351 and P1, respectively — contain a mutation called E484K, “which results in changes in the shape of the virus spike protein such that neutralizing antibodies might not bind as well as it does in the absence of the mutation,” explained Dr. Jay Butler, deputy director for infectious diseases at the U.S. © 2021 HealthDay.

Vaccination 52

Vaccination Vaccine Antibody Immune Response 52

pharmaphorum

JULY 7, 2022

Once the pandemic hit, Moderna teamed up with the US National Institute of Allergy and Infectious Diseases (NIAID) to co-develop the former’s vaccine. Both mRNA vaccines also relied on prior research that highlighted the efficacy of encoding for the spike protein, which creates an improved vaccine antigen. Identifying the threat.

Vaccination 104

Vaccination Vaccine Development Research 104

The Pharma Data

APRIL 27, 2021

to €283 million, reflecting growth of Digestive and Mental Wellness categories as well as Allergy partially offset by the decline of the Pain category. Development for Dupixent ® for grass allergy has been discontinued. At CER, BOI increased 48.6%. The ratio of BOI to net sales was 40.5% (and 27.5% Consumer Healthcare. Change at CER.

Sales 52

Sales Vaccination Vaccine Medicine 52

pharmaphorum

AUGUST 13, 2020

One Pfizer brand getting plenty of attention is Xeljanz, their blockbuster anti-JAK rheumatoid arthritis pill that could damp down the massive immune response that overwhelms some COVID-19 patients.

Branding 112

Branding Vaccination Vaccine Filler 112

The Pharma Data

DECEMBER 29, 2020

The vaccine — which right now is known as NVX-CoV2373 — comes in two doses and is designed to enhance the body’s immune response to the coronavirus’ distinctive spike protein. National Institute of Allergy and Infectious Diseases, said last week. “It very well might be here for all we know.”

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

XTalks

MAY 2, 2024

Some treatments already on the market have grabbed additional approvals in 2024, including Novo Nordisk’s Wegovy (semaglutide) for cardiovascular risk reduction, Dupixent (dupilumab) for eosinophilic esophagitis (EoE) in young children and Xolair (omalizumab) for food allergies.

Drugs 52

Drugs FDA Approval Vaccination Vaccine 52

XTalks

JANUARY 2, 2025

Why it sold so well: On February 16, 2024, the FDA approved omalizumab for reducing allergic reactions, including anaphylaxis, due to accidental exposure to food in adults and children aged one year and older with food allergies.

Sales 85

Sales FDA Approval Drugs Marketing 85

The Pharma Data

DECEMBER 31, 2020

The messenger RNA (mRNA) vaccines encode a form of the spike (S) protein of SARS-CoV-2 virus. The vaccine teaches the cells to make a piece of the spike protein, which triggers an immune response to help prevent illness if later exposed to the virus. The partial piece of the spike protein cannot cause COVID-19 disease.

Vaccination 52

Vaccination Vaccine FDA Approval Hormones 52

pharmaphorum

JULY 26, 2022

At a basic level, the virus’s protein ‘coat’ and the enzymes it uses to gain control of the host cell’s DNA mutate frequently, making it difficult to target with therapeutics. The team found that HIV Pol is formed by two proteins bound together, which was unexpected as other similar viral proteins are single-protein assemblies.

Gene Therapy 140

Gene Therapy Protein Vaccination Vaccine 140

The Pharma Data

MAY 13, 2021

In addition, these vectors carry the genetic code of several Ebola virus proteins in order to trigger an immune response. Johnson & Johnson Ebola Vaccine Regimen The European Commission-approved Johnson & Johnson preventive Ebola vaccine regimen, Zabdeno ® (Ad26.ZEBOV)

Vaccination 52

Vaccination Vaccine Medicine Clinical Trials 52

The Pharma Data

DECEMBER 31, 2020

National Institute of Allergy and Infectious Diseases, Gov. The vaccine — which right now is known as NVX-CoV2373 — comes in two doses and is designed to enhance the body’s immune response to the coronavirus’ distinctive spike protein. It’s to be expected,” Fauci said.

Vaccination 52

Vaccination Vaccine Genetics Protein 52

XTalks

SEPTEMBER 14, 2020

These companies include Moderna, a US biotech company which has formed a partnership with the National Institute of Allergy and Infectious Diseases (NIAID), Oxford University who has partnered with AstraZeneca, and Johnson & Johnson, Merck and Pfizer. University of Oxford and AstraZeneca COVID-19 Vaccine.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92